Premium
Risk of azole‐enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: Old problem – New Dilemma
Author(s) -
Pana Zoe Dorothea,
Roilides Emmanuel
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22972
Subject(s) - medicine , itraconazole , neurotoxicity , vincristine , blood cancer , adverse effect , voriconazole , pharmacology , oncology , triazole , chemotherapy , antifungal , cancer , bioinformatics , toxicity , dermatology , chemistry , organic chemistry , biology , cyclophosphamide
One of the most well‐known drug interactions in pediatric oncology concerns the co‐administration of itraconazole, an antifungal triazole, and vincristine, an antileukemic agent, which seems to enhance the risk of neurotoxicity of the latter, mediated through the cytochrome CYP450 enzyme system. The aim of this article is to review the metabolism of these two drugs, to analyze the published cases with severe triazole‐enhanced vincristine neurotoxicity, to discuss the pathophysiological mechanisms of this adverse effect, and to contribute in understanding the differences in triazole‐vincristine interaction severity. Pediatr Blood Cancer 2011;57:30–35. © 2011 Wiley‐Liss, Inc.